Many of us with chronic obstructive pulmonary disease (COPD) have received medical devices to help with our breathing. At first, it seemed to me that some of these devices worked better than others.
So far Trelegy has been launched in 30 countries and continues to roll out, with recent approvals in Japan and China setting up launches in those big markets later this year.
Trelegy is a key drug for GSK, and analysts predict peak sales in excess of $1billion. The company needs new revenues in respiratory diseases, as its ageing blockbuster inhaler Advair will face ...